Form 4: Indivior Director Receives RSU Grant

Indivior Pharmaceuticals Director Daniel A. Ninivaggi was granted 3,722 Restricted Stock Units, increasing his direct beneficial ownership to 20,645 shares.

Summary

• Director Daniel A. Ninivaggi of Indivior Pharmaceuticals, Inc. was granted 3,722 shares of common stock in the form of Restricted Stock Units (RSUs) on January 26, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the grant date, contingent on Mr. Ninivaggi's continued service to the Issuer.
• Following this transaction, Mr. Ninivaggi's direct beneficial ownership of Indivior Pharmaceuticals common stock totals 20,645 shares.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is a routine compensation event that aligns the director's interests with those of shareholders, indicating continued commitment. This is generally viewed positively as it fosters long-term value creation.

Positives

• The grant of Restricted Stock Units aligns the director's long-term interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.

Risks

• The vesting of the Restricted Stock Units is subject to the Reporting Person's continued service to the Issuer on the vesting date, meaning the shares could be forfeited if service ceases before vesting.

Future Outlook

The Restricted Stock Units are scheduled to vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the grant date, provided the director maintains continuous service.

Industry Context

Equity grants, such as Restricted Stock Units, are a common form of compensation for directors and executives in publicly traded companies. This practice aims to incentivize long-term performance and align the interests of leadership with those of shareholders.

Comparison to Industry Standards

• The grant of Restricted Stock Units to a director is a common practice in public companies for executive and director compensation, aiming to align long-term interests with shareholders. This filing does not provide specific details for direct comparison to other companies' compensation structures or project results.

Related Party Transactions

• Director Daniel A. Ninivaggi received a grant of 3,722 Restricted Stock Units as compensation, which is a transaction with a related party.

Stakeholder Impact

• Shareholders: The equity grant to a director is intended to align the director's financial interests with the long-term performance of the company, potentially benefiting shareholder value.

Next Steps

• The RSUs will vest on the day immediately preceding the first annual meeting of Indivior Pharmaceuticals' stockholders following the grant date, subject to continued service.

Key Dates

Recommendation

The Form 4 filing reports a routine grant of Restricted Stock Units to a director as part of their compensation. This action, while aligning the director's interests with shareholders, does not provide new material information that would alter the fundamental investment thesis for Indivior Pharmaceuticals, Inc. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Indivior Pharmaceuticals, INDV, Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Insider Transaction, Daniel A. Ninivaggi